Premium
Gaucher disease and comorbidities: B‐cell malignancy and parkinsonism
Author(s) -
Cox Timothy M.,
Rosenbloom Barry E.,
Barker Roger A.
Publication year - 2015
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.24057
Subject(s) - glucocerebrosidase , disease , gaucher's disease , glucocerebroside , medicine , lymphoma , immunology , pathogenesis , cancer , pathology
Data emerging from the International Collaborative Gaucher Group (ICGG) Gaucher Registry together with other contemporary clinical surveys have revealed a close association between Gaucher disease and non‐Hodgkin's B‐cell lymphoma and myeloma and Gaucher disease and Parkinson's disease. Several possible explanations for increased B‐cell proliferation and neoplasia in Gaucher disease have been proposed, including the possible influence of sphingosine (derived from the extra lysosomal metabolism of glucosylceramide), gene modifiers, splenectomy and immune system deregulation induced by cytokines, chemokines, and hydrolases released from Gaucher cells. Parkinson's disease is frequently seen in the otherwise‐healthy relatives of Gaucher disease patients leading to the finding that GBA mutations represent a genetic risk factor for Parkinson's disease. The mechanism of the association between GBA mutations and Parkinson's disease has yet to be elucidated but the pathogenesis appears distinct from that of Gaucher disease. Several pathogenic pathways have been proposed including lysosomal and/or mitochondrial dysfunction. The effect of Gaucher disease specific therapies on the incidence of cancer or Parkinson's disease are not clear and will likely be evaluated in future ICGG Gaucher Registry studies. Am. J. Hematol. 90:S25–S28, 2015. © 2015 Wiley Periodicals, Inc.